1
|
Zhou J, Wu X, Zhao C. Optimization of decellularized liver matrix-modified chitosan fibrous scaffold for C3A hepatocyte culture. J Biomater Appl 2022; 37:903-917. [PMID: 35834434 DOI: 10.1177/08853282221115367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Hepatocyte scaffold is an essential part in bioartificial liver device. We have designed a novel hepatocyte scaffold based on porcine liver extracellular matrix (ECM) and chitosan (CTS) fabrics. This CTS-ECM scaffold can improve cell adhesion and proliferation. In the present study, an orthogonal test was designed to optimize the CTS/ECM composite scaffold, in which ECM concentration, EDC concentration and EDC to NHS ratio were taken as factors, proportion of nitrogen element and hydroxyproline content as indicators. The cytocompatibility of the novel scaffold for C3A hepatocytes was analyzed in vitro. The orthogonal test demonstrated that the optimal scaffold should be based on ECM concentration of 5 mg/mL, EDC concentration of 5 mg/mL, and EDC to NHS ratio 1:1. C3A hepatocytes cultured on the optimized CTS-ECM scaffolds showed stronger proliferation and functionality than those on Cytodex3 microcarriers (p < 0.05). The CTS/ECM composite scaffold may be widely used as a promising hepatocyte culture carrier, especially in bioartificial liver support systems.
Collapse
Affiliation(s)
- Junjing Zhou
- Department of Hepatobiliary Surgery, 199193Affiliated Hospital of Jiangnan University, Wuxi, China
| | - Xinglian Wu
- Department of pharmacy, 117969The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
| | - Chaochen Zhao
- Department of Hepatobiliary Surgery, 117969The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
| |
Collapse
|
2
|
Bonfield TL, Sutton MT, Fletcher DR, Folz MA, Ragavapuram V, Somoza RA, Caplan AI. Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium. Stem Cells Transl Med 2021; 10:1202-1216. [PMID: 33943038 PMCID: PMC8284776 DOI: 10.1002/sctm.20-0521] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2020] [Revised: 03/02/2021] [Accepted: 03/22/2021] [Indexed: 12/12/2022] Open
Abstract
Chronic nontuberculous mycobacterial infections with Mycobacterium avium and Mycobacterium intracellulare complicate bronchiectasis, chronic obstructive airway disease, and the health of aging individuals. These insidious intracellular pathogens cause considerable morbidity and eventual mortality in individuals colonized with these bacteria. Current treatment regimens with antibiotic macrolides are both toxic and often inefficient at providing infection resolution. In this article, we demonstrate that human marrow‐derived mesenchymal stem cells are antimicrobial and anti‐inflammatory in vitro and in the context of an in vivo sustained infection of either M. avium and/or M. intracellulare.
Collapse
Affiliation(s)
- Tracey L Bonfield
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.,National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio, USA.,Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Morgan T Sutton
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.,National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio, USA.,Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA.,St. Jude Children's Research Hospital Graduate School of Biomedical Sciences, Memphis, Tennessee, USA
| | - David R Fletcher
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.,National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio, USA.,Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Michael A Folz
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.,National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio, USA.,Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Vaishnavi Ragavapuram
- Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio, USA.,National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio, USA.,Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Rodrigo A Somoza
- Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio, USA
| | - Arnold I Caplan
- Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio, USA
| |
Collapse
|
3
|
Sutton MT, Fletcher D, Episalla N, Auster L, Kaur S, Gwin MC, Folz M, Velasquez D, Roy V, van Heeckeren R, Lennon DP, Caplan AI, Bonfield TL. Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis. ACTA ACUST UNITED AC 2017; 7. [PMID: 29291140 DOI: 10.4172/2157-7633.1000400] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Human Mesenchymal stem cells (hMSCs) secrete products (supernatants) that are anti-inflammatory and antimicrobial. We have previously shown that hMSCs decrease inflammation and Pseudomonas aeruginosa infection in the in vivo murine model of Cystic Fibrosis (CF). Cystic Fibrosis (CF) is a genetic disease in which pulmonary infection and inflammation becomes the major cause of morbidity and mortality. Our studies focus on determining how MSCs contribute to improved outcomes in the CF mouse model centering on how the MSCs impact the inflammatory response to pathogenic organisms. We hypothesize that MSCs secrete products that are anti-inflammatory in scenarios of chronic pulmonary infections using the murine model of infection and inflammation with a specific interest in Pseudomonas aeruginosa (gram negative). Further, our studies will identify whether the MSCs are impacting this inflammatory response through the regulation of peroxisome proliferator activator receptor gamma (PPARγ) which aides in decreasing inflammation.
Collapse
Affiliation(s)
- Morgan T Sutton
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,National Center of Regenerative Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948.,School of Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948.,School of Engineering, Case Western Reserve University, Cleveland Ohio 44106-4948.,Hathaway Brown School, Shaker Heights Ohio 44122.,Summer Programs in Undergraduate Research, Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland Ohio 44106-4948
| | - David Fletcher
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Nicole Episalla
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,Department of Biology, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Lauren Auster
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,Department of Biology, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Sukhmani Kaur
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,Hathaway Brown School, Shaker Heights Ohio 44122
| | - Mary Chandler Gwin
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,Summer Programs in Undergraduate Research, Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland Ohio 44106-4948
| | - Michael Folz
- School of Engineering, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Dante Velasquez
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,National Center of Regenerative Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Varun Roy
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,School of Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Rolf van Heeckeren
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Donald P Lennon
- Department of Biology, Case Western Reserve University, Cleveland Ohio 44106-4948.,Skeletal Research Center, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Arnold I Caplan
- Department of Biology, Case Western Reserve University, Cleveland Ohio 44106-4948.,Skeletal Research Center, Case Western Reserve University, Cleveland Ohio 44106-4948
| | - Tracey L Bonfield
- Department of Pediatrics, Case Western Reserve University, Cleveland Ohio 44106-4948.,National Center of Regenerative Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948.,School of Medicine, Case Western Reserve University, Cleveland Ohio 44106-4948.,Skeletal Research Center, Case Western Reserve University, Cleveland Ohio 44106-4948
| |
Collapse
|
4
|
Choi YR, Chang YJ, Kim SW, Choe KH, Lee KM, An JY. Crazy paving radiography finding in asymptomatic pulmonary alveolar proteinosis. Asian Cardiovasc Thorac Ann 2014; 23:588-90. [PMID: 25182335 DOI: 10.1177/0218492314548232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Pulmonary alveolar proteinosis is a rare disorder characterized by alveolar accumulation of surfactant phospholipids and protein components. The symptoms and prognosis are extremely variable. Bronchoalveolar lavage fluid and/or transbronchial lung biopsy are useful for diagnosis; surgical lung biopsy is often unnecessary but useful in the focal involvement. We report a case of pulmonary alveolar proteinosis in a 50-year-old woman, confirmed by a video-assisted thoracoscopic surgery biopsy from the initial focal involvement, with normal bronchoalveolar lavage and transbronchial lung biopsy findings.
Collapse
Affiliation(s)
- Young Rak Choi
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
| | - You-Jin Chang
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
| | - Si Wook Kim
- Department of Thoracic & Cardiovascular Surgery, Chungbuk National University Hospital, Cheongju, Republic of Korea
| | - Kang Hyeon Choe
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
| | - Ki Man Lee
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
| | - Jin-Young An
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
| |
Collapse
|
5
|
Strickler A, Boza ML, Koppmann A, Gonzalez S. Autoimmune pulmonary proteinosis in a Chilean teenager, a rare aetiology of interstitial lung disease. BMJ Case Rep 2014; 2014:bcr-2012-006987. [PMID: 24859540 DOI: 10.1136/bcr-2012-006987] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Interstitial lung disease (ILD) is rare and encompasses a heterogeneous group of diseases, and is even rarer in children than in adults. ILDs compromise more than 100 different entities, including pulmonary alveolar proteinosis (PAP). There are many causes of PAP in children, including surfactant protein gene mutations (SFTPB, SFTPC, ABCA3, TTF-1), GMCSF receptor mutations and antigranulocyte-macrophage colony-stimulating factor autoantibodies. We report a case of a 13-year-old Chilean girl who presented with an 8-month history of progressive exercise intolerance, fatigability and diminished school performance. Physical examination revealed resting tachypnoea, a few basal bilateral inspiratory crackles, and hypoxaemia on minimal exertion. Clinical suspicion and evaluation, including international collaboration, led to the diagnosis of autoimmune PAP and specific therapy for the condition.
Collapse
Affiliation(s)
- Alexis Strickler
- Department of Service of Paediatrics, Puerto Montt Hospital Chile, Puerto Montt, Chile
| | - Maria Lina Boza
- Department of Paediatric Neumology, San Borja Arriarán Hospital, University of Chile, Santiago, Chile
| | - Andres Koppmann
- Department of Paediatric Neumology, San Borja Arriarán Hospital, University of Chile, Santiago, Chile
| | - Sergio Gonzalez
- Department of Pathology, Pontifical Catholic University of Chile, Santiago, Chile
| |
Collapse
|
6
|
LETH STEFFEN, BENDSTRUP ELISABETH, VESTERGAARD HANNE, HILBERG OLE. Autoimmune pulmonary alveolar proteinosis: Treatment options in year 2013. Respirology 2012; 18:82-91. [DOI: 10.1111/j.1440-1843.2012.02274.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
7
|
Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK. Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol 2011; 32:238-45. [PMID: 22170314 DOI: 10.1007/s10875-011-9621-8] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2011] [Accepted: 11/14/2011] [Indexed: 01/29/2023]
Abstract
BACKGROUND Anticytokine autoantibodies cause numerous human diseases, ranging from pure red cell aplasia to acquired immunodeficiencies. Rapid, simple, and affordable detection and monitoring of these antibodies is essential. We sought to develop a standardizable assay that is rapid, sensitive, and specific and able to simultaneously detect multiple anticytokine autoantibodies in small volumes (<10 μl). METHODS We conjugated purified human cytokines to commercially available fluorescently labeled microspheres and tested them against sera from well-characterized subjects with at least one high-titer, disease-associated anticytokine autoantibody. RESULTS Cytokine-conjugated microspheres efficiently and rapidly determined plasma concentration and IgG subclass of anticytokine autoantibodies in single or multiplex formats. CONCLUSION This particle-based multiplex assay can reproducibly characterize anticytokine autoantibodies. This efficient and inexpensive approach to diagnosing and monitoring anticytokine autoantibodies has clinical applications.
Collapse
Affiliation(s)
- Li Ding
- Laboratory of Clinical Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892-1684, USA
| | | | | | | | | | | |
Collapse
|
8
|
Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011; 38:1361-7. [PMID: 21478218 DOI: 10.1183/09031936.00197710] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Rituximab, a monoclonal antibody directed against the B-lymphocyte antigen CD20, has shown promise in several autoimmune disorders. Pulmonary alveolar proteinosis (PAP) is an autoimmune disorder characterised by autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF). An open-label, proof-of-concept phase II clinical trial was conducted in 10 PAP patients. The intervention consisted of two intravenous infusions of rituximab (1,000 mg) 15 days apart. Bronchoalveolar lavage (BAL) fluid and peripheral blood samples were collected. The primary outcome was improvement in arterial blood oxygenation. Both arterial oxygen tension and alveolar-arterial oxygen tension difference in room air improved in seven out of the nine patients completing the study. Lung function and high-resolution computed tomography scans, which were secondary outcomes, also improved. Peripheral blood CD19+ B-lymphocytes decreased from mean ± sem 15 ± 2% to <0.05% (n = 10) 15 days post-therapy. This decrease persisted for 3 months in all patients; at 6 months, CD19+ B-cells were detected in four out of seven patients (5 ± 2%). Total anti-GM-CSF immunoglobulin (Ig)G levels from baseline to 6 months were decreased in BAL fluids (n = 8) but unchanged in sera (n = 9). In this PAP cohort: 1) rituximab was well-tolerated and effectively ameliorated lung disease; and 2) reduction in anti-GM-CSF IgG levels in the lung correlated with disease changes, suggesting that disease pathogenesis is related to autoantibody levels in the target organ.
Collapse
Affiliation(s)
- M S Kavuru
- Division of Pulmonary, East Carolina University, Brody School of Medicine, 3E-149 Brody Medical Sciences Building, Greenville, NC 27834, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. JOURNAL OF INFLAMMATION-LONDON 2010; 7:51. [PMID: 20974000 PMCID: PMC2987779 DOI: 10.1186/1476-9255-7-51] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Accepted: 10/25/2010] [Indexed: 01/27/2023]
Abstract
Allogeneic human mesenchymal stem cells (hMSCs) can suppress graft versus host disease (GvHD) and have profound anti-inflammatory and regenerative capacity in stroke, infarct, spinal cord injury, meniscus regeneration, tendinitis, acute renal failure, and heart disease in human and animal models of disease. There is significant clinical hMSC variability in efficacy and the ultimate response in vivo. The challenge in hMSC based therapy is defining the efficacy of hMSC in vivo. Models which may provide insight into hMSC bioactivity in vivo would provide a means to distinguish hMSCs for clinical utility. hMSC function has been described as both regenerative and trophic through the production of bioactive factors. The regenerative component involves the multi-potentiality of hMSC progenitor differentiation. The secreted factors generated by the hMSCs are milieu and injury specific providing unique niches for responses in vivo. These bioactive factors are anti-scarring, angiogenic, anti-apoptotic as well as regenerative. Further, from an immunological standpoint, hMSC's can avoid host immune response, providing xenographic applications. To study the in vivo immuno-regulatory effectiveness of hMSCs, we used the ovalbumin challenge model of acute asthma. This is a quick 3 week in vivo pulmonary inflammation model with readily accessible ways of measuring effectiveness of hMSCs. Our data show that there is a direct correlation between the traditional ceramic cube score to hMSCs attenuation of cellular recruitment due to ovalbumin challenge. The results from these studies verify the in vivo immuno-modulator effectiveness of hMSCs and support the potential use of the ovalbumin model as an in vivo model of hMSC potency and efficacy. Our data also support future directions toward exploring hMSCs as an alternative therapeutic for the treatment of airway inflammation associated with asthma.
Collapse
Affiliation(s)
- Tracey L Bonfield
- Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA.
| | | | | | | |
Collapse
|
10
|
Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol 2010; 299:L760-70. [PMID: 20817776 DOI: 10.1152/ajplung.00182.2009] [Citation(s) in RCA: 154] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Allogeneic human mesenchymal stem cells (hMSCs) introduced intravenously can have profound anti-inflammatory activity resulting in suppression of graft vs. host disease as well as regenerative events in the case of stroke, infarct, spinal cord injury, meniscus regeneration, tendinitis, acute renal failure, and heart disease in human and animal models of these diseases. hMSCs produce bioactive factors that provide molecular cuing for: 1) immunosuppression of T cells; 2) antiscarring; 3) angiogenesis; 4) antiapoptosis; and 5) regeneration (i.e., mitotic for host-derived progenitor cells). Studies have shown that hMSCs have profound effects on the immune system and are well-tolerated and therapeutically active in immunocompetent rodent models of multiple sclerosis and stroke. Furthermore, intravenous administration of MSCs results in pulmonary localization. Asthma is a major debilitating pulmonary disease that impacts in excess of 150 million people in the world with uncontrolled asthma potentially leading to death. In addition, the socioeconomic impact of asthma-associated illnesses at the pediatric and adult level are in the millions of dollars in healthcare costs and lost days of work. hMSCs may provide a viable multiaction therapeutic for this inflammatory lung disease by secreting bioactive factors or directing cellular activity. Our studies show the effectiveness and specificity of the hMSCs on decreasing chronic airway inflammation associated with the murine ovalbumin model of asthma. In addition, the results from these studies verify the in vivo immunoeffectiveness of hMSCs in rodents and support the potential therapeutic use of hMSCs for the treatment of airway inflammation associated with chronic asthma.
Collapse
Affiliation(s)
- Tracey L Bonfield
- Dept. of Pediatrics, Case Western Reserve Univ., Cleveland, OH 44106-4948, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Ferbas J, Thomas J, Hodgson J, Gaur A, Casadevall N, Swanson SJ. Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2007; 14:1165-72. [PMID: 17634512 PMCID: PMC2043303 DOI: 10.1128/cvi.00157-07] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Immunogenicity profiles of recombinant therapeutic proteins are important to understand because antibodies raised against these molecules may have important clinical sequelae. The purpose of the present study was to demonstrate that a flow cytometric bead array could be used to detect clinically relevant antibodies with specificity to such therapeutics. We chose to evaluate well-characterized specimens from persons treated with epoetin alfa that developed antibody-mediated pure red blood cell aplasia as a means to demonstrate the utility of this platform. Our data show that this assay is capable of detecting anti-epoetin alfa antibodies with a relative antibody concentration of 50 ng/ml, where 25 of 25 sera spiked with antibodies at this concentration scored positive. Moreover, the assay was designed to include positive and negative control beads for each specimen that is processed to ensure the specificity of the signal when detected. Measurement of interassay precision supports quantitative estimates of relative antibody concentrations in the range of 313 to 5,000 ng/ml, where the percent coefficient of variation did not exceed 20%. With respect to clinical specimens, antibodies with specificity for epoetin alfa could be easily detected in a set of specimens from persons with pure red blood cell aplasia that had prior exposure to the EPREX brand of recombinant epoetin alfa. Further development and validation of this approach may facilitate successful widespread application of the method for detection of anti-epoetin alfa antibodies, as well as antibodies directed against other recombinant therapeutic proteins.
Collapse
Affiliation(s)
- John Ferbas
- Department of Clinical Immunology, Amgen Inc., One Amgen Center Drive, Mailstop 30E-3-C, Thousand Oaks, CA 91320-1799, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Ling MM, Ricks C, Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn 2007; 7:87-98. [PMID: 17187487 DOI: 10.1586/14737159.7.1.87] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Enzyme-linked immunosorbent assays (ELISA) are frequently used for quantitative measurement of the presence of protein, for single-analyte testing, in a sample. The application of ELISA in a microarray format has the potential to simultaneously measure the presence and/or concentrations of numerous proteins, in multiplex testing, all contained in a small drop of test fluid. Microspot microarray technology, in combination with protein biomarkers and nucleic acid diagnostics, appears to be the future high-performance analytical platform of choice. Validation of a large number of disease markers in both molecular and protein diagnostics has paved the way for the emergence of the multiplex assay. Initially, simple low-throughput multiplex assays were tested using the immunoassay format. These were followed by low-level multiplexing and high-throughput array-based immunoassays. More recently, two types of high-level multiplexing and high-throughput diagnostic methods using microspot arrays and bead arrays have been successfully developed to complement single-analyte assays. The value in rapid diagnostic evaluation for high-throughput multiplex, diagnostic test systems based on sound assay design must take into account data screening, normalization and statistical evaluation of possible concentration measurement, data errors and automated operation. Benefits of using multiplex array platforms include improved-quality patient care, as well as cost effectiveness and time saving. These multiplex methods also set the stage for future protein/nucleic acid codetection. Currently, the one analyte at a time test scheme is still dominant; nonetheless, the multiplex microspot microarray tests evaluated in a single multiassay analyzer are expected to become a significant part of clinical diagnostic testing within the next 5-10 years. This review is focused on microspot array and bead array methods for providing high throughput and a high degree of multiplexing in diagnostic testing.
Collapse
Affiliation(s)
- Michael M Ling
- umedik Inc., 36 Meteor Drive, Toronto, Ontario M9W 1A4, Canada.
| | | | | |
Collapse
|
13
|
Bonfield TL, Barna BP, John N, Malur A, Culver DA, Kavuru MS, Thomassen MJ. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun 2006; 26:37-41. [PMID: 16337108 DOI: 10.1016/j.jaut.2005.10.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2005] [Revised: 10/10/2005] [Accepted: 10/21/2005] [Indexed: 12/01/2022]
Abstract
Pulmonary alveolar proteinosis (PAP) is an autoimmune disorder characterized by neutralizing autoantibodies to granulocyte-macrophage colony stimulating factor (GM-CSF). Surfactant metabolism is severely dysregulated in PAP, resulting in a foam cell appearance of alveolar macrophages. Microarray analysis of RNA from PAP bronchoalveolar lavage (BAL) cells to explore autoimmune-related genes yielded evidence of a deficiency of activin A, a cytokine implicated in regulation of B-cell proliferation and reduction of foam cell formation. Subsequent studies confirmed a severe deficiency of activin A gene expression and protein secretion in PAP BAL cells and marked reduction of activin A protein in PAP BAL fluids compared to healthy controls. PAP cells, however, like those of healthy controls, were capable of elevated activin A production in response to GM-CSF. Treatment with activin A in vitro suppressed proliferation of PAP peripheral blood B-cells in a receptor-dependent manner and also reduced secretion of anti-GM-CSF autoantibody. These studies are the first to suggest that activin A may play a role in autoimmune disease.
Collapse
Affiliation(s)
- Tracey L Bonfield
- Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland, OH, USA
| | | | | | | | | | | | | |
Collapse
|